<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371627</url>
  </required_header>
  <id_info>
    <org_study_id>V712-EAP01</org_study_id>
    <nct_id>NCT04371627</nct_id>
  </id_info>
  <brief_title>Viaskin® Peanut (DBV712) Expanded Access Protocol</brief_title>
  <official_title>Viaskin® Peanut (DBV712) Expanded Access Protocol in Peanut-Allergic Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DBV Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DBV Technologies</source>
  <brief_summary>
    <textblock>
      This is an open label expanded access program for male and female patients ≥ 4 years old.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label Intermediate-size EAP designed to provide treatment access for&#xD;
      eligible Peanut-Allergic Children. This EAP entails visits every three months to assess&#xD;
      patient status, safety, and to provide drug supply. Viaskin® Peanut treatment will continue&#xD;
      until, in the clinical judgment of the Investigator, the patient is no longer benefiting from&#xD;
      continuation of the treatment, the drug becomes approved and available by prescription, or&#xD;
      the study is terminated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Peanut Allergy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viaskin Peanut</intervention_name>
    <description>Daily epicutaneous delivery</description>
    <other_name>DBV712</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥ 4 years of age&#xD;
&#xD;
          -  Prior participation in a Viaskin® Peanut REALISE or PEOPLE clinical study for&#xD;
             peanut-allergic patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation or planning a pregnancy.&#xD;
&#xD;
          -  Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled&#xD;
             generalized active eczema, ichthyosis vulgaris) extending widely on the skin and&#xD;
             especially on the back with no intact zones to apply the Viaskin® patches.&#xD;
&#xD;
          -  Patients who developed hypersensitivity to excipients of the Viaskin® patches.&#xD;
&#xD;
          -  Received or planning to receive anti-tumor necrosis factor drugs or anti-IgE drugs&#xD;
             (such as omalizumab) or any biologic immunomodulatory therapy.&#xD;
&#xD;
          -  Receiving or planning to receive any other type of immunotherapy to any food (for&#xD;
             example, EPIT, OIT, or SLIT or specific oral tolerance induction) or any aeroallergen&#xD;
             or venom immunotherapy during their participation in the study.&#xD;
&#xD;
          -  Use of cyclosporine or other immunosuppressive agents within 3 months before entering&#xD;
             the study. Topical calcineurin inhibitors are permitted.&#xD;
&#xD;
          -  A history of important non-compliance during the REALISE or PEOPLE studies. Important&#xD;
             non-compliance includes patients not applying the patches for 60 or more days in total&#xD;
             and/or for 30 or more consecutive days during the REALISE or PEOPLE studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peanut allergy</keyword>
  <keyword>EPIT</keyword>
  <keyword>Epicutaneous</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Viaskin®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

